Cancer InformationYour Pathway to Patient Centered Information

Top 20 Cancer Drugs

Best Selling Oncology Drugs Include Herceptin and Avastin

Oncology medications are booming business for the pharmaceutical industry. Nearly all of the major companies are either currently manufacturing oncology drugs or have oncology medications in their pipeline as potential medications in coming years.

High Cost for Oncology Medications

Cancer is one of the most dreaded diagnoses a patient can get. In the past, cancer used to mean a death sentence But recent developments in the pharmaceutical industry have made cancer treatable and even curable, in some cases.

Cancer affects millions of people each year, as the world population continues to grow, the rate of new cancer cases will grow too.

Cancer is a brutal disease, and patients are willing to spend even extreme high costs in order to manage their illnesses. In terms of business, oncology medications are the strongest guarantee of high revenue.

Many of the new medications are geared towards very specific kinds of cancer, charging premium prices and facing little competition. And because biologic treatments do not have the same kind of generic competition as chemical drugs, they have a longer shelf-life in terms of patent protections.

The pharmaceutical industry’s 20 top-selling cancer drugs generate sales over $50 billion worldwide. Roche’s Rituxan, Avastin and Herceptin lead the pack, with $21 billion in sales for these three drugs alone. Roche’s top oncology line represented about 40 percent of the top 20 in combined sales.

While about 20 oncology drugs are now classified as blockbusters, earning a billion or more in sales each year, experts predict there will be at least 29 oncology blockbusters by 2018.

International Demand

There is an increasing demand worldwide for oncology medications, so pharmaceutical companies are seeing significant growth outside of their usual markets in the United States and Europe. Rising healthcare spending in Asian countries like China and Japan make medications more accessible. An expanding middle class in India, partially due to the influx of pharmaceutical companies outsourcing manufacturing to Indian factories, makes medical care possible. And as markets in Japan and the United States age and cancer becomes more common, the demand for oncology medications will only grow.
Pharmaceutical companies will increasingly focus their efforts on developing, testing and launching new medications in the oncology therapeutic area to meet customer demand.

Avastin

Manufacturer: Roche
Condition or Diseases treated: Breast, colorectal, lung, kidney, ovarian cancers
Global Sales: $6.7 billion
Generic name: Bevacizumab

Revlimid

Manufacturer: Celgene
Condition or Diseases treated: Multiple myeloma
Global Sales: $4.2 billion
Generic name: Lenalidomide

Rituxan

Manufacturer: Roche
Condition or Diseases treated: Non-Hodgkins Lymphoma, chronic lymphocytic leukemia
Global Sales: $7.5 billion
Generic name: Rituximab

Herceptin

Manufacturer: Roche
Condition or Diseases treated: HER2+ breast cancer
Global Sales: $6.5 billion
Generic name: Trastuzumab

Imbruvica

Manufacturer: Johnson & Johnson/Pharmacyclics
Condition or Diseases treated: Mantel cell lymphoma, chronic lymphocetic leukemia
Global Sales: $5.3 billion
Generic name: Ibrutinib capsules

Gleevec

Manufacturer: Novartis
Condition or Diseases treated: Chronic myeloid leukemia, gostrointestinal stromal tumors
Global Sales: $4.7 billion
Generic name: Imatinib

Alimta

Manufacturer: Eli Lilly
Condition or Diseases treated: Non-small cell lung cancer
Global Sales: $2.5 billion
Generic name: Pemetrexed

Velcade

Manufacturer: Johnson & Johnson/Takeda
Condition or Diseases treated: Multiple myeloma, mantle cell lymphoma
Global Sales: $2.6 billion
Generic name: Bortezomib

Erbitux

Manufacturer: BMS/Merck Serono
Condition or Diseases treated: Colorectal, head and neck cancers
Global Sales: $1.9 billion
Generic name: Cetuximab

Gardasil

Manufacturer: Merck & Co.
Condition or Diseases treated: Cervical cancer
Global Sales: $1.8 billion
Generic name: Human Papillomavirus Quadrivalent (Types 6,11, 16, and 18) Vaccine, Recombinant]

Zytiga

Manufacturer: Johnson & Johnson
Condition or Diseases treated: Prostate cancer
Global Sales: $1.7 billion
Generic name: Abiraterone acetate

Xeloda

Manufacturer: Roche
Condition or Diseases treated: Breast, colorectal cancers
Global Sales: $1.6 billion
Generic name: Capecitabine

Tarceva

Manufacturer: Roche
Condition or Diseases treated: Non-small-cell lung, pancreatic cancers
Global Sales: $1.4 billion
Generic name: Erlotinib

Afinitor

Manufacturer: Novartis
Condition or Diseases treated: Breast cancer
Global Sales: $1.3 billion
Generic name: Everolimus

Tasigna

Manufacturer: Novartis
Condition or Diseases treated: Chronic myeloid leukemia
Global Sales: $1.3 billion
Generic name: Nilotinib

Sutent

Manufacturer: Pfizer
Condition or Diseases treated: Renal cell sarcoma, gastrointestinal stromal tumors
Global Sales: $1.2 billion
Generic name: Sunitinib Malate

Nexavar

Manufacturer: Bayer
Condition or Diseases treated: Renal cell sarcoma, liver cancer
Global Sales: $1 billion
Generic name: Sorafenib

Xgeva

Manufacturer: Amgen
Condition or Diseases treated: Bone mestases
Global Sales: $1 billion
Generic name: Denosumab

Zoladex

Manufacturer: AstraZeneca
Condition or Diseases treated: Breast, prostate cancer
Global Sales: $1 billion
Generic name: Goserelin acetate

Yervoy

Manufacturer: BMS
Condition or Diseases treated: Melanoma
Global Sales: $960 million
Generic name: Ipilimumab

Author: Kathlyn Stone

Source: https://www.thebalance.com/top-cancer-drugs-2663234




Leave a Reply

Your email address will not be published. Required fields are marked *